Eli Lilly’s Covid-19 drug bamlanivimab is no longer distributed in 3 states because of a variant, Woodcock says
The US government is no longer distributing Eli Lilly’s bamlanivimab into California, Arizona and Nevada because of the prevalence of a viral variant that is not susceptible to the monoclonal antibody, FDA acting commissioner Janet Woodcock told physicians taking part in a webinar with the American Medical Association on Wednesday.
Woodcock did not elaborate further on the variant or the decision to halt the distribution, but overall, the FDA remains uniquely positioned to screen the monoclonals against the different variants, Woodcock added, and that’s been predictive of how and where the treatments will work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.